The peer-reviewed evidence summarized below is drawn from studies of each compound separately
According to their respective PK profiles, exenatide BID and lixisenatide can be categorized as short-acting agents (each has a half-life of 35 h) compared with the long-acting agents liraglutide, exenatide LAR, albiglutide, and dulaglutide, which have half-lives ranging from 12 h to several days [16]
However, if your GLP1R gene carries loss-of-function variants, your maximum natural output may always be insufficient, making semaglutide therapy a more reliable solution
mitek K, mitek J, Rogl Butina M, Hristov H, Poganik T, Pravst I
Beaded Lizards and Gila Monsters, Captive Care and Husbandry